Skip to content

Clinical study on the treatment of early and middle stage knee osteoarthritis with Wenjing Tongluo Paste and Babu

Clinical study on the treatment of early and middle stage knee osteoarthritis with Wenjing Tongluo Paste and Babu

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081210
Enrollment
Unknown
Registered
2024-02-26
Start date
2024-03-02
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Treatment group:Wenjing Tongluo Paste, 1 patch a day, every 12 hours, stick for 4 weeks
Celecoxib, 0.2g orally, 1 capsule once a day for 1 week. Glucosamine hydrochloride capsules, taken orally, 1 capsule 3 times a day for 4 weeks.
Control group:Wenjing Tongluo Ointment and placebo were applied 1 patch a day, every 12 hours, for 4 weeks

Sponsors

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Patients who meet the diagnostic criteria of Western medicine and TCM syndrome differentiation criteria of KOA; ? Age 40-75 years old, gender is not limited; ? Kellgren-Lawrance (K-L) X-ray grading was used to grade I-III. VAS score 4-7 points; ? No steroid or non-steroidal anti-inflammatory and analgesic drugs were used within 3 months before enrollment, and no other related treatment was received; ? Patients who have signed informed consent and guaranteed to complete the treatment course and follow-up.

Exclusion criteria

Exclusion criteria: ? A woman who is breastfeeding, pregnant or preparing to become pregnant; ? Have a history of multiple drug allergy; ? Severe primary diseases of liver, kidney, hematopoietic system, endocrine system, cardiovascular and cerebrovascular system, nervous system, etc.; Patients with tuberculosis, vertebral deformity, malignant tumor and mental illness; Suspected history of sedative hypnotics, opioid analgesics and alcohol abuse; Patients with skin diseases and infectious diseases; History of gastric ulcer and gastric bleeding; ? Patients who should not or cannot use this treatment for other reasons; ? Patients with mental disorders, language disorders, motor dysfunction, mental illness can not cooperate.

Design outcomes

Primary

MeasureTime frame
WOMAC Osteoarthritis Index questionnaire;

Secondary

MeasureTime frame
VAS visual analogue pain score;Tinetti Balance and Gait Analysis Scale score;TCM syndrome scale score;Serum levels of interleukin-6 (IL-6), interleukin-1ß (IL-1ß) and tumor necrosis factor-a (TNF-a) were measured by ELISA.;

Countries

China

Contacts

Public ContactWen Mo

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

tcmzsm@163.com+86 187 3999 6659

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026